Emergent BioSolutions Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $51.8m $82.6m $62.7m $54.5m $305.1m $230.9m ($211.6m) ($760.5m) ($190.6m) $52.6m
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $51.8m $62.7m
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $62.5m $82.6m $62.7m
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($10.7m) $0 $0
Depreciation, Depletion and Amortization $28.0m $32.2m $36.3m $49.5m $50.1m $123.8m $143.3m $125.1m $108.8m $95.8m
Depreciation $38.2m $42.6m $62.2m $110.7m $114.5m $62.2m $83.4m $59.5m $43.7m $30.7m
Amortization of Debt Issuance Costs $781k $681k ($13.4m) $3.0m $3.5m $4.1m $4.1m $21.3m $7.4m $9.8m
Amortization of Intangible Assets $6.9m $8.6m $25.0m $58.7m $59.8m $58.5m $59.9m $65.6m $65.1m $65.1m
Deferred Income Tax Expense (Benefit) $5.2m $3.3m $8.6m ($1.1m) ($2.4m) $43.9m ($33.7m) ($7.3m) ($5.5m) ($3.9m)
Share-based Payment Arrangement, Noncash Expense $18.5m $15.2m $23.2m $26.7m $51.0m $42.4m $45.1m $23.1m $18.0m $16.2m
Payment, Tax Withholding, Share-based Payment Arrangement $4.3m $6.6m $7.4m $13.8m $13.8m $5.9m $2.5m $1.2m $1.4m
Share-based Payment Arrangement, Expense $18.5m $15.2m $23.2m $26.7m $51.0m $42.4m $45.1m $23.1m $18.0m $16.2m
Goodwill, Impairment Loss $0 $0 $41.7m $6.7m $218.2m $0 $0
Impairment of Intangible Assets, Finite-lived $12.0m $29.0m
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $701k $0 $41.7m $6.7m
Gain (Loss) on Disposition of Assets ($28.7m) ($4.5m)
Gain (Loss) on Disposition of Business $74.2m $24.3m $0
Gain (Loss) on Extinguishment of Debt $0 $0 $2.5m $600k ($12.2m)
Income Tax Expense (Benefit) $36.7m $36.0m $18.8m $22.9m $102.1m $83.5m ($7.4m) $29.3m $47.7m $30.2m
Interest Expense Nonoperating $71.0m $59.3m
Operating Lease, Lease Income $30.5m $62.1m
Other Nonoperating Income (Expense) $263k ($815k) $1.6m $1.7m $4.7m ($3.7m) ($11.7m) $8.9m $12.5m $54.2m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $22.4m $4.8m $94.2m $8.2m ($49.0m) $48.2m ($118.1m) $21.6m $24.4m ($25.5m)
Increase (Decrease) in Inventories $9.0m ($6.1m) $1.9m $16.7m $83.2m $44.0m $57.1m ($600k) $24.5m $30.3m
Increase (Decrease) in Accounts Payable ($14.8m) $16.1m ($7.0m) $16.5m $19.8m ($2.5m) ($14.0m) $10.6m ($33.0m) ($8.4m)
Proceeds from Stock Options Exercised $17.1m $19.3m $15.9m $8.2m $0 $500k $0 $0 $2.2m
Goodwill $41.0m $49.1m $259.7m $266.6m $266.7m $224.9m $218.2m $0 $0 $0
Investment Income, Interest $1.1m $1.8m
Nonoperating Income (Expense) ($6.3m) ($5.7m) ($8.3m) ($36.7m) ($26.6m) ($38.2m) ($49.0m) ($4.8m) ($34.2m) ($17.3m)
Operating Costs and Expenses $1.1b $1.4b $1.3b $1.8b $1.2b $642.8m
Operating Expenses $692.6m $991.9m
Pension Cost (Reversal of Cost) $1.0m $2.4m $2.0m $800k $600k $0 $0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement ($1.0m) $0 $400k $0
Net Cash Provided by (Used in) Operating Activities $53.5m $208.1m $41.8m $188.0m $536.0m $321.1m ($34.1m) ($206.3m) $58.7m $170.6m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $76.3m $54.8m $72.1m $86.9m $141.0m $225.0m $115.8m $51.6m $22.9m $13.8m
Payments to Acquire Businesses, Net of Cash Acquired $0 $195.1m $827.7m $0 $0
Net Cash Provided by (Used in) Investing Activities ($76.3m) ($249.9m) ($897.2m) ($96.9m) ($151.0m) ($225.0m) ($381.3m) $212.3m $125.2m $69.4m
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt $0 $0 $798.0m $0 $0 $219.0m $0
Repayments of Long-term Debt $0 $2.8m
Proceeds from Issuance of Common Stock $19.3m $15.9m $8.2m $0 $0 $8.4m $0 $0
Payments for Repurchase of Common Stock $0 $33.1m $100k $0 $0 $106.0m $82.1m $0 $0 $24.9m
Net Cash Provided by (Used in) Financing Activities ($19.8m) ($51.4m) $788.7m ($35.9m) $69.5m ($141.0m) $481.2m ($535.7m) ($190.0m) ($136.6m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $100k $0 ($200k) $400k ($1.0m) ($300k) $500k ($1.2m) $0 $100k
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $100k $0 ($200k) $55.6m $453.5m ($45.2m) $66.3m ($530.9m) ($6.1m) $103.5m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $100k $0 $112.4m $168.0m $621.5m $576.3m $642.6m $111.7m $105.6m $209.1m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $8.2m $8.4m $10.2m $34.5m $21.0m $30.4m $33.0m $68.3m $64.0m $49.7m
Income Taxes Paid, Net $10.1m $12.0m $14.0m $30.8m $109.3m $71.6m $6.2m $52.8m $26.5m $40.0m

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.